MedDay Announces Full Enrollment for MD1003 Phase III

Biotin is an emerging therapy for the treatment of secondary progressive MS.
Post Reply
User avatar
ton
Family Member
Posts: 78
Joined: Thu May 27, 2010 2:00 pm

MedDay Announces Full Enrollment for MD1003 Phase III

Post by ton »

Post Reply
  • Similar Topics
    Replies
    Views
    Last post

Return to “Biotin (Qizenday, Cerenday, MD1003)”